RCKT

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Militello JohnSee Remarks $018k shares OtherMay 26, 2026 $1.1M18k shares $62.32 --
Militello JohnSee Remarks $049.8k shares OtherMay 26, 2026 $998.0K49.8k shares $20.04 --
Militello JohnSee Remarks $024.5k shares OtherMay 26, 2026 $736.6K24.5k shares $30.01 --
Militello JohnSee Remarks $027k shares OtherMay 26, 2026 $514.4K27k shares $19.05 --
Militello JohnSee Remarks $020k shares OtherMay 26, 2026 $454.4K20k shares $22.72 --
Militello JohnSee Remarks $018k shares OtherMay 26, 2026 $446.8K18k shares $24.82 --

News

seekingalpha.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 9

seekingalpha.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Jefferies Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 5

businesswire.comRocket Pharmaceuticals to Participate in Upcoming Investor Conferencesbusinesswire.comMay 28

zacks.comRCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focuszacks.comMay 11

businesswire.comRocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progressbusinesswire.comMay 7

Trade RCKT

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.

CEO: Gaurav D. Shah
IPO Date: Feb 18, 2015

Market Data

Open: $2.90
High: $2.92
Low: $2.69
Volume: 2.6M
52W High: $5.45
52W Low: $2.40

Valuation

Market Cap: $300M
Enterprise Value: $275M

Financials

Free Cash Flow: $-190M
Revenue: $0
Net Income: $-223M
Cash: $78M
Debt: $25M

Events

EarningsAug 6

EPS est. 1.04